Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OCUP
- Price
- 1.13
- Stock movement down
- -0.04 (-3.42%)
- Company name
- Ocuphire Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 29.60M
- Ent value
- -7.61M
- Price/Sales
- 1.80
- Price/Book
- 0.73
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -61.69%
- 3 year return
- -36.00%
- 5 year return
- -31.84%
- 10 year return
- -43.50%
Last updated: 2024-12-17
DIVIDENDS
OCUP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.80 |
| Price to Book | 0.73 |
| EV to Sales | -0.46 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.20M |
| EPS (TTM) | -0.55 |
| FCF per share (TTM) | -0.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 16.45M |
| Gross profit (TTM) | 11.42M |
| Operating income (TTM) | -15.08M |
| Net income (TTM) | -14.11M |
| EPS (TTM) | -0.55 |
| EPS (1y forward) | -0.90 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 69.40% |
| Operating margin (TTM) | -91.67% |
| Profit margin (TTM) | -85.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 41.41M |
| Net receivables | 2.31M |
| Total current assets | 44.83M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 25.00K |
| Total assets | 44.83M |
| Accounts payable | 634.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 4.20M |
| Total liabilities | 4.20M |
| Shareholder's equity | 40.64M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.46M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -11.46M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.71% |
| Return on Assets | -31.46% |
| Return on Invested Capital | -34.71% |
| Cash Return on Invested Capital | -28.21% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.19 |
| Daily high | 1.20 |
| Daily low | 1.10 |
| Daily Volume | 177K |
| All-time high | 1008000.00 |
| 1y analyst estimate | 13.67 |
| Beta | 0.31 |
| EPS (TTM) | -0.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 May 2025 |
Downside potential
Loading...
Downside potential data
| OCUP | S&P500 | |
| Current price drop from All-time high | -100.00% | -0.92% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 24 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -99.74% | -11.07% |
| Avg time to new high | 2249 days | 12 days |
| Max time to new high | 4495 days | 1805 days |
COMPANY DETAILS
Marketcap
29.60M
Marketcap category
Small-cap
Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner